$EMBC

Embecta Corp. (EMBC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 q32026ex-991.htm EX-99.1 Document FOR IMMEDIATE RELEASE Embecta Corp. Reports Third Quarter Fiscal 2026 Financial Results PARSIPPANY, N.J., Aug 7, 2026 (GLOBE NEWSWIRE) – Embecta Corp. (“embecta” or the "Company") (Nasdaq: EMBC), a global diabetes care company, today re

Bleichmar Fonti & Auld LLP said it filed a securities fraud class action against Embecta Corp. (NASDAQ:EMBC) and executives after the stock fell 57.8% on May 5, 2026. The complaint alleges Embecta overstated the strength of its insulin pen needle category despite competition and market softness. It cites Q2 results below guidance and a dividend cut from $0.15 to $0.01.

BTIG downgraded Embecta Corp. (NASDAQ: EMBC) from Buy to Neutral and Wolfe Research issued a negative note after Embecta cut FY2026 guidance about 40%. The article cites revised EPS of $1.55 to $1.75, revenue down 17.4% (adjusted constant currency), and a dividend cut from $0.15 to $0.01. It also notes an Aug. 17, 2026 lead plaintiff deadline.

Bleichmar Fonti & Auld LLP said a securities-fraud class action was filed against Embecta Corp. (NASDAQ:EMBC) and executives, alleging misstatements about the strength of its insulin pen needle category. The suit follows Embecta’s May 5, 2026 stock drop of 57.8% after Q2 results missed guidance; the firm cites a dividend cut from $0.15 to $0.01. Lead plaintiff deadline: Aug. 17, 2026.

Embecta Corp. (Nasdaq: EMBC) said management will participate in several investor events in June 2026: one-on-one meetings at the Jefferies Global Healthcare Conference (June 3, NYC), a fireside session at the TD Cowen Diabetes Tech Summit (June 5, 9:40 a.m. CT), one-on-one meetings at the Goldman Sachs 47th Annual Global Healthcare Conference (June 9, Miami), and one-on-one meetings at the Truist Securities MedTech Conference (June 16, Boston).

Embecta Corp, a pure-play diabetes-care company, recently updated investors with its latest quarterly figures and guidance, drawing attention from US healthcare investors. The company focuses on insulin-delivery solutions, providing reliable devices like pen needles and syringes. While facing cost pressures and competition, Embecta aims to maintain margins and gradually reduce debt through cost-control initiatives and strategic expansions.

Embecta (EMBC) reported significantly weaker-than-expected Q2 fiscal 2026 results, with revenue down 14.4% and a net loss of $4.1 million. The company slashed its full-year 2026 guidance, citing U.S. market headwinds, but simultaneously announced a three-year, $100 million share repurchase program and reduced its quarterly dividend from $0.15 to $0.01 per share to reallocate capital towards buybacks and debt reduction. Management still plans to repay approximately $150 million in debt in 2026 and expects the Owen Mumford acquisition to close in May 2026, adding revenue but diluting EPS.

Embecta Corp. (NASDAQ:EMBC) has declared a quarterly cash dividend of $0.01 per share, which will be paid on June 15, 2026, to shareholders of record as of May 28, 2026. This dividend represents an annual yield of 6.49%, and InvestingPro tips highlight Embecta for its significant dividend payments. The company recently reported strong fiscal first-quarter 2026 earnings, surpassing analyst expectations, and announced the acquisition of Owen Mumford Holdings Limited.

BTIG analyst Marie Thibault reiterated a Buy rating on Embecta Corporation, maintaining a $22 price target. This positive outlook is based on the company's resilient core diabetes business, consistent financial performance despite market challenges, and strategic expansion into a broader medical supplies platform, including opportunities related to GLP-1 and the upcoming Owen Mumford acquisition. Thibault believes the company's disciplined execution and future growth optionality justify its current valuation.

Embecta Corp specializes in insulin delivery systems, benefiting from the growing prevalence of diabetes in the U.S. and English-speaking markets. The company's focused business model, key products like insulin pens and syringes, and strong competitive position in the medical device space make it a relevant investment for those seeking exposure to stable healthcare spending. Despite cautious optimism from analysts and risks such as intensifying competition, Embecta's niche in essential diabetes care positions it favorably for long-term growth.